Advertisement

FDA approves semaglutide for type 2 diabetes

Share This Page
FDA has approved semaglutide (Ozempic—Novo Nordisk) as an adjunct to diet and exercise for the treatment of type 2 diabetes in adults. The drug, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, was approved in 0.5-mg and 1.0-mg doses, to be administered once a week with a dedicated prefilled pen device.

FDA has approved semaglutide (Ozempic—Novo Nordisk) as an adjunct to diet and exercise for the treatment of type 2 diabetes in adults. The drug, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, was approved in 0.5-mg and 1.0-mg doses, to be administered once a week with a dedicated prefilled pen device. Following approval, Novo Nordisk must conduct a pediatric trial in individuals younger than age 18 years and add semaglutide to a 15-year medullary thyroid carcinoma registry that includes all of the long-acting GLP-1 products. According to a company spokesperson, semaglutide will be priced similarly to current weekly GLP-1 receptor agonists and will be offered with a savings card program.

Ad Position: 
Bottom Center Aligned
https://www.medscape.com/viewarticle/889631

Advertisement

Related Content

block-views-related-content-block